This study was undertaken to assess an instant results protocol for first-trimester combined screening.
How accurate is combined screening, based on maternal age, using serum and nuchal translucency measurements in first trimester screening for Down and Edward syndromes?
Areas with high densities of all 3 diseases were designated "hot spots". Combined screening for tuberculosis, HIV, and syphilis were conducted at the hot spots; participants with positive tests were referred to the health department.
Receptor models were selected based on their combined screening performance, as determined by the normalised square root area under the curve, NSQ_AUC.
We assessed whether combined screening using BPD, AFP, and other serum markers at 11-13 would would increase detection.
The distinction between ultrasound and combined screening in our data may be blurred as some ultrasounds might have been performed as part of an intended combined test but where the biochemical screening was not carried out.
In all, 16% of cases were diagnosed following a first positive indication from serum/ combined screening, (range from 0% in Germany, Ireland, Spain and Ukraine to 49% in Switzerland and 60% in Denmark), (Figure 5).
To investigate whether first trimester combined screening for major fetal trisomies is influenced by assisted reproduction techniques from blastocyst transfer, with or without cryopreservation.
Combined screening for chromosome abnormalities in the first trimester of pregnancy is based on maternal age, nuchal translucency (NT) and biochemical markers (PAPP-A and free β-hCG).
We sought to determine efficacy of minor markers for detection of Down syndrome (DS) in a population prescreened with first-trimester combined screening (FTS).
We sought to assess the value of the variables used in the combined screening strategy taking into account maternal gravidity and foetal gender.
